KR102851614B1 - 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법 - Google Patents

장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법

Info

Publication number
KR102851614B1
KR102851614B1 KR1020187023566A KR20187023566A KR102851614B1 KR 102851614 B1 KR102851614 B1 KR 102851614B1 KR 1020187023566 A KR1020187023566 A KR 1020187023566A KR 20187023566 A KR20187023566 A KR 20187023566A KR 102851614 B1 KR102851614 B1 KR 102851614B1
Authority
KR
South Korea
Prior art keywords
domperidone
release
formulation
active agent
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187023566A
Other languages
English (en)
Korean (ko)
Other versions
KR20180104662A (ko
Inventor
캐서린 피어스
존 이삭손
피유시 파텔
Original Assignee
신돔 파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신돔 파마, 인크. filed Critical 신돔 파마, 인크.
Publication of KR20180104662A publication Critical patent/KR20180104662A/ko
Application granted granted Critical
Publication of KR102851614B1 publication Critical patent/KR102851614B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020187023566A 2016-02-04 2017-02-03 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법 Active KR102851614B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291198P 2016-02-04 2016-02-04
US62/291,198 2016-02-04
PCT/US2017/016334 WO2017136617A1 (en) 2016-02-04 2017-02-03 Deuterated domperidone compositions and methods for therapy of disorders

Publications (2)

Publication Number Publication Date
KR20180104662A KR20180104662A (ko) 2018-09-21
KR102851614B1 true KR102851614B1 (ko) 2025-08-29

Family

ID=59501077

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187023566A Active KR102851614B1 (ko) 2016-02-04 2017-02-03 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법
KR1020207002879A Active KR102695402B1 (ko) 2016-02-04 2018-06-28 중수소화 돔페리돈 조성물, 방법, 및 제조

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207002879A Active KR102695402B1 (ko) 2016-02-04 2018-06-28 중수소화 돔페리돈 조성물, 방법, 및 제조

Country Status (11)

Country Link
US (2) US10266516B2 (enExample)
EP (2) EP3411031B1 (enExample)
JP (3) JP7296185B2 (enExample)
KR (2) KR102851614B1 (enExample)
CN (4) CN108697700B (enExample)
AU (2) AU2017213852B2 (enExample)
BR (2) BR112018016032B1 (enExample)
CA (2) CA3013123A1 (enExample)
DK (2) DK3411031T3 (enExample)
EA (2) EA035515B1 (enExample)
WO (2) WO2017136617A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
KR102851614B1 (ko) 2016-02-04 2025-08-29 신돔 파마, 인크. 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
KR20240125702A (ko) 2017-06-30 2024-08-19 신돔 파마, 인크. 중수소화 돔페리돈 조성물, 방법, 및 제조
KR20210022558A (ko) * 2018-06-21 2021-03-03 더마반트 사이언시즈 게엠베하 Dgat1 억제제의 국소 제형 및 이의 사용 방법
EP3681502B1 (en) * 2018-10-25 2021-03-17 CinDome Pharma, Inc. Formulations containing domperidone
CA3117682A1 (en) * 2018-10-25 2020-04-30 Cindome Pharma, Inc. Formulations containing deuterated domperidone
WO2022212246A1 (en) * 2021-03-29 2022-10-06 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Multi-enzyme nanoparticle-assisted stable isotope incorporation into small molecules by channeling
US20250268884A1 (en) * 2022-04-20 2025-08-28 Cindome Pharma, Inc. Deuterated Domperidone for Treating Gastroparesis
CN120813355A (zh) * 2023-03-23 2025-10-17 辛多美制药有限公司 用于治疗糖尿病性胃轻瘫的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255096A1 (en) * 2007-04-26 2010-10-07 Aronchick Craig A Compositions And Methods For Transmucosal Delivery Of Domperidone

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
TW466119B (en) * 1994-02-28 2001-12-01 Janssen Pharmaceutica Nv Film coated tablet of paracetamol and domperidone
FR2725986B1 (fr) * 1994-10-21 1996-11-29 Adir Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US20140070440A1 (en) 2001-10-12 2014-03-13 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20140163060A1 (en) 2001-10-12 2014-06-12 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20160206639A9 (en) 2001-10-12 2016-07-21 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20130220526A1 (en) 2001-10-12 2013-08-29 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
ITMI20020514A1 (it) 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
DK1545475T3 (da) 2002-10-01 2014-07-28 Banner Pharmacaps Inc Enterisk sammensætning til fremstillingen af blød kapselvæg
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
CN104083342A (zh) 2004-12-31 2014-10-08 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
ITMI20050477A1 (it) 2005-03-23 2006-09-24 Bouty S P A Cerotto transdermico
CN100386323C (zh) * 2006-02-27 2008-05-07 南京长澳医药科技有限公司 马来酸多潘立酮的合成方法
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
CN102895194B (zh) 2006-06-30 2015-09-09 伊休蒂卡有限公司 用于制备纳米粒形式的生物活性化合物的方法
JP5345620B2 (ja) 2007-08-15 2013-11-20 マクニール−ピーピーシー・インコーポレーテツド 即時放出及び徐放型イブプロフェンの投与法
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090076010A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
WO2009146310A1 (en) 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
US20100113405A1 (en) * 2008-11-06 2010-05-06 Auspex Pharmaceuticals, Inc. Methylindazole modulators of 5-ht3 receptors
WO2010054158A2 (en) * 2008-11-07 2010-05-14 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
MY159208A (en) 2009-04-24 2016-12-30 Iceutica Pty Ltd A novel formulation of indomethacin
EP2421525B1 (en) 2009-04-24 2017-06-07 Iceutica Pty Ltd. Diclofenac formulation
CN102438592B (zh) 2009-04-24 2016-09-14 伊休蒂卡有限公司 甲氧萘普酸的剂型
WO2010121324A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A novel formulation of metaxalone
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
US20140017299A1 (en) 2011-08-18 2014-01-16 Monosol Rx, Llc Steroid hormone delivery systems and methods of preparing the same
CN107441069A (zh) 2012-02-28 2017-12-08 日绊株式会社 贴附剂
SMT202500302T1 (it) 2012-06-15 2025-09-12 Sun Pharmaceutical Industries Inc Derivati deuterati del ruxolitinib
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
US20140019395A1 (en) 2012-07-12 2014-01-16 Craig Charles Bauer Method and application of Fear, Love and Methodology as protocols within and of a programming group, as a means of creating an artificial individual, software system or other independent entity capable of independent self directive creation of choice and/or self directive creation of purpose within a virtual and/or any environment
EP2968334A4 (en) 2013-03-14 2016-08-03 Deuterx Llc 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
US20140272220A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Reduction in stress cracking of films
US20140271787A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Continuous single layer film structure including discrete domains
CN105246598B (zh) 2013-03-15 2019-09-13 太阳药业环球公司 乙酸阿比特龙酯制剂
KR102851614B1 (ko) 2016-02-04 2025-08-29 신돔 파마, 인크. 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255096A1 (en) * 2007-04-26 2010-10-07 Aronchick Craig A Compositions And Methods For Transmucosal Delivery Of Domperidone

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Organic Square, 33, pp.2-3(2010) 1부.*
Toronto research chemicals inc., Safety data sheet, catalogue # D531102 1부.*
Xenobiotica, 43(12), pp.1073-83(2013.05.23.) 1부.*

Also Published As

Publication number Publication date
EA035515B1 (ru) 2020-06-29
CN108697700B (zh) 2021-08-17
EP3411031A4 (en) 2019-08-07
CN113995755A (zh) 2022-02-01
CN111093653A (zh) 2020-05-01
AU2018290905B2 (en) 2022-10-06
AU2017213852A1 (en) 2018-07-05
JP7296185B2 (ja) 2023-06-22
JP2020534246A (ja) 2020-11-26
WO2019006078A1 (en) 2019-01-03
BR112019028185A8 (pt) 2020-08-11
BR112018016032A2 (pt) 2018-12-26
JP2019504068A (ja) 2019-02-14
EA201891727A1 (ru) 2018-12-28
US20190241543A1 (en) 2019-08-08
CN108697700A (zh) 2018-10-23
KR20180104662A (ko) 2018-09-21
EA202090183A1 (ru) 2020-04-15
JP2023052045A (ja) 2023-04-11
US10590110B2 (en) 2020-03-17
US10266516B2 (en) 2019-04-23
BR112018016032B1 (pt) 2024-03-05
CA3013123A1 (en) 2017-08-10
EP3411031B1 (en) 2024-07-24
AU2017213852B2 (en) 2021-04-08
CA3055777A1 (en) 2019-01-03
EP3644995B1 (en) 2025-05-07
WO2017136617A1 (en) 2017-08-10
EP3411031A1 (en) 2018-12-12
DK3411031T3 (da) 2024-10-21
JP7602324B2 (ja) 2024-12-18
KR102695402B1 (ko) 2024-08-16
US20170298046A1 (en) 2017-10-19
BR112019028185A2 (pt) 2020-07-07
CN116712432A (zh) 2023-09-08
WO2017136617A8 (en) 2017-10-05
CN111093653B (zh) 2023-06-23
DK3644995T3 (da) 2025-08-18
EP3644995A1 (en) 2020-05-06
KR20200044790A (ko) 2020-04-29
AU2018290905A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
KR102851614B1 (ko) 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법
EP3592337B1 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
US11364226B2 (en) Deuterated domperidone compositions, methods, and preparation
US12478612B2 (en) Deuterated domperidone compositions, methods, and preparation
ES3034905T3 (en) Deuterated domperidone compounds for use in ameliorating gastroesophageal reflux disease
HK40064919A (en) Deuterated domperidone compositions and methods for therapy of disorders
HK40029064B (en) Deuterated domperidone compounds for use in ameliorating gastroesophageal reflux disease
HK40029064A (en) Deuterated domperidone compounds for use in ameliorating gastroesophageal reflux disease
EA045546B1 (ru) Способ облегчения заболевания или состояния, связанного с моторикой желудочно-кишечного тракта, с использованием дейтерированного домперидона
HK40001556A (en) Deuterated domperidone compositions and methods for therapy of disorders
HK40001556B (en) Deuterated domperidone compositions and methods for therapy of disorders
HK1259508A1 (en) Deuterated domperidone compositions and methods for therapy of disorders
HK1259508B (zh) 氘代多潘立酮组合物和用於治疗病症的方法
BR112019016091B1 (pt) Unidade de dosagem oral e uso de floroglucinol e trimetilfloroglucinol

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601